Introduction
============

Amyotrophic lateral sclerosis (ALS) is a devastating progressive neurodegenerative disease, which causes death within 3--4 years from symptom onset.[@b1-ndt-14-193] The etiology of disease is still not well understood, resulting in a lack of really effective disease-modifying therapies. To date, riluzole is the only drug approved to treat ALS; riluzole has been demonstrated to delay invasive mechanical ventilation or death for several months.[@b2-ndt-14-193]--[@b5-ndt-14-193] Only recently, a new drug, edaravone, was approved by the Food and Drug Administration (FDA).[@b6-ndt-14-193] Riluzole blocks glutamate-mediated excitatory neurotransmission attenuating excitotoxicity, one of the proposed pathophysiological pathways of neuronal death. Riluzole tablet was the only available formulation until 2014, when the oral suspension (OS) formulation has been approved. Considering that dysphagia is a symptom experienced by the majority of patients during the natural history of disease, one of the reasons for therapy discontinuation is just the tablet formulation therapy. Therefore, the OS riluzole 5 mg/mL certainly provides more advantages to the dysphagic patients, thus improving therapeutic outcome and quality of life.[@b7-ndt-14-193]

Previous studies explored the safety and tolerability of riluzole therapy in patients who have been included in one of the two international, multicenter, randomized, double-blind, placebo-controlled trials[@b8-ndt-14-193] or who have not been eligible for clinical trials but had access to drug, while it was under the review of regulatory agencies.[@b9-ndt-14-193] The overall tolerability of riluzole was good, and the treatment was indicated for all patients with ALS, except for those with hepatic disease and/or who had an increase in transaminase (\>3, the upper limit).[@b10-ndt-14-193]

An important worldwide public health problem in the management of chronic diseases is the medication adherence and persistence. Adherence is defined as "the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen."[@b11-ndt-14-193] Adherence has been studied in many chronic illnesses, such as HIV infection,[@b12-ndt-14-193] hypertension,[@b13-ndt-14-193] diabetes,[@b14-ndt-14-193] epilepsy,[@b15-ndt-14-193] multiple sclerosis[@b16-ndt-14-193] and psychiatric disorders.[@b17-ndt-14-193] Overall, an average adherence of only 50% is indicated by the World Health Organization among patients with chronic diseases.[@b18-ndt-14-193] The adherence to riluzole therapy in patients with ALS has not been evaluated yet.

The aim of our observational study was to examine the adherence to riluzole in the 2 available formulations in patients with ALS and the potential factors that can influence it.

Patients and methods
====================

Study population
----------------

We enrolled 45 consecutive patients with ALS referring to the Tertiary Centre of Motor Neuron Disease of our department from August 2016 to January 2017, followed until February 2017. The date of diagnosis ranged from January 2011 to August 2016.

All the included patients were prescribed with riluzole and vitamin E at disease diagnosis. Until 2014, all the patients received riluzole tablet; after 2014, either tablet or OS of riluzole was prescribed according to the presence and severity of dysphagia. At the time of observation, 21 patients had definite, 7 probable, 4 laboratory-supported probable and 13 possible ALS, according to El Escorial-r criteria.[@b19-ndt-14-193] After obtaining informed consent, a clinical questionnaire, specifically structured for the study in object, was administered by a neurologist to all patients in the presence of a family member or caregiver. Demographic and clinical data, including actual age, sex, age at symptom onset, site of onset (bulbar or spinal), disease duration from symptom onset to interview, symptom onset to therapy start interval (OTI), duration of therapy at interview, follow-up duration, ALS Functional Rating Scale -- revised (ALSFRS-r) and Manual Muscle Testing -- medium (MMT-m) at observation, time to generalization (TTG; time interval between disease spreading from spinal to bulbar district or vice versa) and progression rate (48 -- ALSFRS-r)/month of disease duration were collected (Supplementary material). Information on the specific treatment for ALS (tablets or OS of riluzole), their side effects (SEs) and other co-medications were recorded (see [Figure S1](#SD1-ndt-14-193){ref-type="supplementary-material"}). Patients taking OS of riluzole reported also a qualitative opinion (pleasant, unpleasant or indifferent) about aroma, color, consistency and flavor of the drug. Finally, Italian version of ©Morisky 8-item Medication Adherence Questionnaire was used to assess the adherence to riluzole and other concomitant medications.[@b20-ndt-14-193]--[@b23-ndt-14-193]

The study was approved by the local independent ethics committee of the Regional University Hospital of Bari, Italy.

Statistical analysis
--------------------

Statistical analysis was performed using IBM SPSS Statistics 20 (IBM Corporation, Armonk, NY, USA). Group comparison was computed using Mann--Whitney/Wilcoxon test for 2 independent samples and with *χ*^2^ test or Fisher's exact text for nominal variables. The relationship between the rate of adherence to riluzole and the number of medications or clinical parameters was assessed by multinomial logistic regression. Statistical significance was considered when *p*-values were \<0.05.

Results
=======

Clinical features
-----------------

At the time of diagnosis, 27/45 patients (17 males) received tablets and 18/45 patients received OS (10 males) of riluzole. The bulbar onset was significantly more frequent in the OS group (14/18 in the OS group and 4/27 in the tablet group), and all but 2 patients of this group reported dysphagia (13/18 in the OS group and 3/27 in the tablet group) at diagnosis. In the tablet group, although a slight dysphagia at diagnosis was reported in 11 patients, it did not influence the intake of tablets. The 2 groups did not differ in terms of age at disease onset, OTI, duration of riluzole assumption at the time of interview, time of interview from therapy initiation, duration of disease from symptom onset to interview, follow-up duration, ALSFRS-r and TTG, whereas MMT-m was lower in the tablet group ([Table 1](#t1-ndt-14-193){ref-type="table"}).

During the follow-up (range 1.5--6 months), 8 patients shifted from tablets to OS and 4 patients shifted from OS to tablets, as given in the "Change of riluzole formulation" section. The 2 groups did not differ in terms of OTI, duration of riluzole assumption, TTG, age at onset, ALSFRS-r, MMT-m and progression rate at interview.

Opinion about OS of riluzole
----------------------------

A total of 26 patients on OS of riluzole (18 patients since the study inclusion and 8 patients who shifted from tablet to OS during the follow-up) reported a qualitative opinion about the OS. Fragrance, color and consistency were considered not relevant in the majority of patients. The flavor was unpleasant in 14 patients (53.8%), 12 of whom considered the flavor was very strongly unpleasant ([Figure 1](#f1-ndt-14-193){ref-type="fig"}).

SE profile
----------

In patients in both the tablet and OS groups, the most frequent SE involved the gastrointestinal apparatus. No serious SEs related to treatment were reported. [Figure 2](#f2-ndt-14-193){ref-type="fig"} shows the frequency of SE for apparatus.

The SEs occurring in \>10% of patients were dysgeusia (22.2%) and abdominal pain (11.1%) in the tablet group, whereas oral paresthesia (38.9%), dysgeusia (33.3%) and nausea (11.1%) in the OS group. A detailed list of SEs recorded by patients is reported in [Table 2](#t2-ndt-14-193){ref-type="table"}.

In patients who changed the formulation therapy during the follow-up period, gastroenteric and neurological symptoms remained the most frequent SEs with both the formulations (data not shown).

Change of riluzole formulation
------------------------------

During the follow-up, 8 tablet-group patients shifted to OS riluzole, 7 of whom (87.5%) experienced a severe worsening of dysphagia that limited the assumption of the tablets; only 1 patient experienced a severe gastrointestinal SE.

Four patients shifted from OS to tablet of riluzole for SEs affecting both the gastrointestinal and nervous systems (50%, respectively). Two of these patients considered that the flavor of the OS was unpleasant.

Four out of 45 patients (8.9%) permanently discontinued the riluzole for SEs affecting both the gastrointestinal and nervous systems, some of them even after changing formulation.

Adherence
---------

The rate of adherence (high, medium, low) to riluzole therapy was independent of the formulation of the drug (*χ*^2^, *p*=ns). Even considering only the patients with bulbar onset and dysphagia at diagnosis, the rate of adherence to riluzole therapy was independent of the formulation of the drug (*p*=ns, Fisher's exact test).

When examining the adherence to the specific formulation of the riluzole, 9 patients showed high, 9 medium and 9 low adherence to riluzole tablet (33.3%, respectively). The low adherence to riluzole tablets was related to SEs (mostly gastroenteric) in 5 out of 9 patients (55.6%) who considered them so intolerable to stop therapy (2 patients), to change the formulation (1 patient) or to reduce the posology (2 patients), whereas in the remaining 4 patients (44.4%), it was related to dysphagia. In medium adherence group, a progressive dysphagia limited the adherence in 3 patients, who shifted to OS of riluzole during the follow-up. In the high adherence group, the SEs, if present, were considered tolerable. In the OS group, 8 patients had low adherence to riluzole (44.4%) prevalently (75%) depending on SEs affecting the nervous system or gastrointestinal apparatus, which caused the change of formulation in 3 patients. Seven patients showed medium adherence (38.9%) and 3 (16.7%) high adherence. Seven out of 18 patients who received OS, independently of the rate of adherence, defined the OS as unpleasant flavor. In the subgroup of patients with bulbar onset and dysphagia, the low adherence was mainly related to SEs independently of the formulation of riluzole.

Considering the therapies assumed for comorbidities, the rate of adherence to riluzole was consistent with other medications (*χ*^2^ 15.4, *p*=0.004). In addition, no relationship was found between the number of medications and the rate of adherence to riluzole (*p*=ns).

When the relationships between the rates of adherence to riluzole and clinical features were evaluated, patients with high or medium adherence to riluzole, independently of the formulation, had more likely a higher progression rate (pseudo R^2^=0.179, *p*=0.002 and *p*=0.009, respectively) and a shorter TTG (pseudo R^2^=0.391 and *p*=0.01 for both), in comparison with those with low adherence.

Discussion
==========

This is the first study that evaluates the adherence to the different formulations of riluzole in patients with ALS.

The adherence to medication could be influenced by different factors classifiable into those related to medication (route of administration and type of formulation, polypharmacy, SE), demographic features (sex, age, social class and ethnic group), disease characteristics (severity and clinical parameters) and patient's perception and attitude (treatment of asymptomatic diseases, patients' belief in the benefit of therapy).[@b24-ndt-14-193] Nonadherence to medication is a crucial problem in chronic diseases,[@b25-ndt-14-193] because patients who do not adhere to or persist with therapy are unlikely to receive full benefits of treatment and to achieve better clinical outcomes.[@b16-ndt-14-193]

In chronic diseases, findings on the influence of route of administration/drug formulation on the adherence to treatment are conflicting.[@b26-ndt-14-193],[@b27-ndt-14-193] The first finding of our study is that the rate of adherence or persistence to riluzole was not affected by the formulation of the therapy. The lack of relationship between the rate of adherence and the 2 formulations of riluzole was confirmed also in the subgroup of patients with bulbar onset and dysphagia at the diagnosis of disease, suggesting that the dysphagia was not the main factor limiting the intake of tablet or OS of riluzole.

Although half of the patients that assumed oral suspension of riluzole considered the drug was unpleasant to taste, this was not a reason for low adherence. Instead, the low adherence was mainly due to SEs in both treatment groups, in 75% of cases with OS and in 55.6% with tablet formulation. However, in the tablet group, the progression of the disease, in particular the involvement of bulbar functions with severe dysphagia, was responsible for the low adherence in a substantial proportion of patients (44.4%). Examining the complained SEs, the most frequent disturbances were at the gastrointestinal system in both treatment groups, followed by those at the nervous system in the OS group. Oral paresthesia was reported only in patients taking OS in a high percentage (38.9%), although the novel composition of the aqueous vehicle was designed to minimize the local anesthetic effect of the drug in the mouth.[@b7-ndt-14-193] Our findings disagree with the technical data sheet of riluzole[@b28-ndt-14-193] that reports oral paresthesia generally in a low percentage of patients (1.6%), reflecting the frequency of SE obtained in clinical trials and observational studies.[@b2-ndt-14-193],[@b3-ndt-14-193],[@b8-ndt-14-193]--[@b10-ndt-14-193] Furthermore, in our study, the frequencies of liver function abnormalities, asthenia and nausea were relatively low, with respect to other reports.[@b2-ndt-14-193],[@b3-ndt-14-193],[@b8-ndt-14-193]

In 4 out of 45 patients (8.9%), the SEs were responsible for a permanent riluzole interruption. This percentage was lower than the discontinuation rates reported in randomized studies[@b2-ndt-14-193],[@b3-ndt-14-193] and quite similar to that in observational studies.[@b8-ndt-14-193]--[@b10-ndt-14-193] Although low, this percentage may be remarkable considering that riluzole is one of the few therapies approved for this disease, unlike other diseases as multiple sclerosis in which several drugs of almost equal efficacy are available.[@b29-ndt-14-193]

Another finding of our study is that the polypharmacy did not influence the adherence to riluzole. We speculate that the severity of the ALS could induce a higher adherence such as reported for other severe diseases (ie, cancer or HIV/AIDS).[@b30-ndt-14-193],[@b31-ndt-14-193]

An interesting result is that the adherence to the therapy was directly related to the progression rate of the disease and inversely related to the TTG, suggesting that a rapid diffusion of the disease leads to take therapy with greater continuity, hoping to stop the disease progression. This finding was consistent with the literature data.[@b32-ndt-14-193],[@b33-ndt-14-193]

Although there are some strengths of this study, there are some limitations to be considered: 1) the relative small number of patients and 2) the lack of information about the cognitive profile of patients who could influence the adherence to the therapies. However, we feel that this aspect has not biased our results because the questionnaire was administered in the presence of a family member or caregiver who could confirm the accuracy of the answers provided by the patient.

The evaluation of the adherence to riluzole is relevant; although for a correct interpretation of our results, further studies with a higher number of patients, taking into account their clinical profile, are needed.

Supplementary materials
=======================

###### 

Questionnaire on clinical and pharmacological features related to ALS and comorbidities.

**Abbreviations:** ALS, amyotrophic lateral sclerosis; ALSFRS-r, ALS Functional Rating Scale -- revised; MMT-m, Manual Muscle Testing -- medium; NSAIDs, nonsteroidal anti-inflammatory drugs.

We thank Dr Antonio Leo who was involved in the conception and drawing up of the clinical questionnaire. Use of the ©MMAS is protected by US copyright laws. Permission for use is required and was obtained for this study. A license agreement is available from Donald E Morisky, MMAS Research LLC, 14725 NE 20th Street, Bellevue, WA 98007, USA, or from <dmorisky@gmail.com>.

**Author contributions**

Isabella Laura Simone and Eustachio D'Errico conceived and designed the study. Eustachio D'Errico, Alessandro Introna, Boris Modugno and Isabella Laura Simone performed the experiments. Alessandro Introna, Eustachio D'Errico, Boris Modugno and Isabella Laura Simone analyzed the data. Eustachio D'Errico, Alessandro Introna, Eugenio Distaso, Antonio Scarafino, Angela Fraddosio, Irene Tempesta and Antonella Mastronardi contributed to acquisition of data, Alessandro Introna and Isabella Laura Simone drafted the paper. Isabella Laura Simone drafted/revised the manuscript for content, including medical writing for content, study concept or design, analysis or interpretation of data, statistical analysis and study supervision and coordination. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

**Disclosure**

The authors report no conflicts of interest in this work.

![Qualitative opinion about organoleptic characteristics of OS of riluzole.\
**Abbreviation:** OS, oral suspension.](ndt-14-193Fig1){#f1-ndt-14-193}

![Percentages of SEs for apparatus in the riluzole tablet and OS groups.\
**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; OS, oral suspension; SE, side effect.](ndt-14-193Fig2){#f2-ndt-14-193}

###### 

Clinical features of patients who received tablet and OS of riluzole

  Clinical features                                    Tablet of riluzole (n=27)   OS of riluzole (n=18)   *p*-value
  ---------------------------------------------------- --------------------------- ----------------------- ----------------------------------------------------
  Sex (M/F)                                            17/10                       10/8                    ns
  Age at onset                                         61.84±9.97                  66.80±9.39              ns
  Spinal/bulbar at onset                               23/4                        4/14                    0.00002[\*](#tfn1-ndt-14-193){ref-type="table-fn"}
  Dysphagia at diagnosis                               11 (40.7%)                  16 (88.9%)              0.001[\*\*](#tfn2-ndt-14-193){ref-type="table-fn"}
  Disease duration from symptom onset to interview     49.9±96.48                  29.4±14.1               ns
  OTI (months)                                         13.99±9.03                  19.47±13.27             ns
  Duration of therapy at interview (months)            14.57±22.38                 9.1±7.05                ns
  Follow-up period (months)                            3.7±0.98                    4.3±1.2                 ns
  Time to interview from therapy initiation (months)   19.57±26.28                 10.87±7.3               ns
  MMT-m at interview                                   7.8±1.13                    8.82±1.35               0.0009[\^](#tfn3-ndt-14-193){ref-type="table-fn"}
  ALSFRS-r at interview                                31.74±7.57                  34.17±7.27              ns
  TTG (months)                                         14.36±13.78                 10.79±10.53             ns
  Progression rate at interview                        0.71±0.56                   0.59±0.60               ns

**Notes:**

*χ*^2^=17.8;

*χ*^2^=10.4;

Kruskal--Wallis H=10.9.

**Abbreviations:** ALSFRS-r, ALS Functional Rating Scale -- revised; MMT-m, Manual Muscle Testing -- medium; ns, not significant; OS, oral suspension; OTI, symptom onset to therapy start interval; TTG, time to generalization.

###### 

Detailed list of SEs reported by patients (%)

  --------------------------------------------------------------------
                               Tablet of riluzole\   OS of riluzole\
                               (n=27) (%)            (n=18) (%)
  ---------------------------- --------------------- -----------------
  Gastrointestinal apparatus                         

   Burning mouth syndrome      0                     1 (5.6)

   Hypersalivation             1 (3.7)               1 (5.6)

   Dyspepsia                   1 (3.7)               1 (5.6)

   Nausea                      2 (7.4)               2 (11.1)

   Diarrhea                    1 (3.7)               0

   Abdominal pain              3 (11.1)              1 (5.6)

   Dysgeusia                   6 (22.2)              6 (33.3)

  Nervous system                                     

   Headache                    1 (3.7)               1 (5.6)

   Drowsiness                  1 (3.7)               1 (5.6)

   Asthenia                    2 (7.4)               1 (5.6)

   Dizziness                   1 (3.7)               0

   Limb paresthesia            1 (3.7)               0

   Oral paresthesia            0                     7 (38.9)

   Cramps                      1 (3.7)               0

  AST/ALT increase (≥2 ULN)    2 (7.4)               1 (5.6)

  Respiratory system                                 

   Dyspnea                     1 (3.7)               0

  Skin                                               

   Rash                        0                     1 (5.6)

  Cardiovascular apparatus                           

   Arrhythmia                  0                     1 (5.6)
  --------------------------------------------------------------------

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; OS, oral suspension; SE, side effect; ULN, upper limit of normal.
